Sign in
  1. Home
  2. Companies
  3. Medifast
  4. Financial Ratios
Medifast logo
Medifast MED
$ 12.18 0.16%
report update icon

Quarterly report 2026-Q2
added 08-03-2026

Medifast Financial Ratios 2025-2008 | MED

Brief overview of Medifast's valuation multiples

Current figures are compared with the company's own five-year history for 2020–2024.

The current valuation set is P/E 83.69x (median 13.18x), EV/EBITDA 10.07x (median 17.38x), P/S 0.31x (median 0.49x). The current ratio basket stands about 37.8% below the five-year comparison base. Earnings and risk trends should explain the discount.

At the current P/E, inverse earnings yield is 1.2%, a useful bridge between price and business earnings.

Current measures of operating quality are ROE -9.4%, ROA -7.5%, ROCE -7.1%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

Price, earnings and growth produce a PEG of 0.2x. A value below one indicates moderate pricing relative to expected growth.

The time from paying for inputs to receiving cash fell from 58.1 days to 40.5 days. Cash turnover improved.

Conclusion

Medifast trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.

Annual Financial Ratios Medifast

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

 -6.2 87.5 5.3 8.3 13.2 28.1 14.8 26.8 30.2 27.8 17.3 30.5 15.1 20.5 12.4 21.5 12.4 -

P/S

 0.3 0.3 0.5 0.7 1.4 3.1 1.6 3.0 2.8 1.8 1.3 1.4 1.0 0.9 0.8 1.6 0.8 -

EPS

 -1.7 0.2 9.1 12.8 14.0 8.7 6.6 4.7 2.3 1.5 1.7 1.0 1.7 1.2 1.3 1.4 0.8 -

EV (Enterprise Value)

 78 M 158 M 543 M 1.27 B 2.25 B 2.84 B 1.17 B 1.47 B 799 M 468 M 334 M 412 M 360 M 325 M 248 M 428 M 130 M -973 K

EBITDA per Share

 - 1.43 12.8 17.5 19.1 11.8 8.13 6.15 3.68 2.72 2.99 3.02 3.26 2.51 2.56 2.66 1.76 -

EV/EBITDA

 2690.2 10.1 3.9 6.5 10.1 18.4 11.3 19.2 17.4 13.7 8.5 9.9 7.2 8.4 6.2 11.4 5.5 -

PEG

 0.19 -25.72 0.26 0.21 0.27 0.83 0.36 0.26 0.56 -2.74 0.28 -0.76 0.3 -1.58 -2.88 - - -

P/B

 0.6 0.8 2.6 7.7 10.7 18.4 11.0 13.7 7.7 5.2 3.9 5.0 3.7 3.6 3.1 5.9 - -

P/CF

 17.2 7.1 3.6 6.1 22.9 19.9 15.6 26.7 20.9 22.0 13.1 21.7 11.8 11.3 11.4 14.7 7.4 -

ROE %

 -9.55 0.95 49.14 92.88 81.01 65.41 74.32 51.13 25.53 18.58 22.64 16.38 24.35 17.49 25.26 27.25 23.75 -

ROA %

 -7.66 0.70 31.94 45.54 41.18 37.26 40.03 32.93 19.00 14.71 17.10 11.37 18.07 12.19 17.55 20.85 - -

ROCE %

 -7.15 1.37 62.74 119.20 106.80 85.32 78.98 63.30 36.43 27.75 30.59 34.00 31.82 22.92 32.06 43.97 38.68 -

Current Ratio

 5.1 3.8 2.9 2.0 2.0 2.3 1.9 2.4 3.4 4.1 3.7 3.0 3.4 3.1 3.2 4.3 - -

DSO

 - - - - 0.1 0.4 0.7 0.7 0.7 1.8 2.2 2.1 1.3 2.2 1.8 0.4 - -

DIO

 103.4 112.2 106.9 119.1 106.9 78.7 100.7 117.2 95.7 97.0 68.1 75.5 74.0 85.6 98.9 54.8 - -

DPO

 62.9 72.0 56.9 49.4 48.8 44.9 46.7 65.7 79.9 50.8 57.5 58.4 59.9 66.8 - - - -

Operating Cycle

 103.4 112.2 106.9 119.1 107.0 79.1 101.4 117.9 96.4 98.9 70.3 77.6 75.3 87.8 100.7 55.2 - -

Cash Conversion Cycle

 40.5 40.2 50.0 69.7 58.1 34.1 54.7 52.2 16.4 48.1 12.8 19.2 15.4 21.0 100.7 55.2 - -

All numbers in USD currency

Quarterly Financial Ratios Medifast

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 -0.28 -0.19 -0.21 0.23 -0.07 - 0.1 -0.75 0.76 - 2.12 2.78 3.68 - 3.3 3.44 3.62 - 3.59 4 3.49 2.38 2.93 1.86 1.57 1.71 1.36 1.8 1.75 1.32 1.15 1.17 1.02 0.61 0.56 0.64 0.52 0.35 0.51 0.29 0.36 - 0.46 0.51 0.36 - 0.39 0.44 0.45 - 0.41 0.51 0.43 - 0.53 0.2 0.29 - 0.37 0.42 0.44

EBITDA per Share

 0.23 0.02 - - 0.18 - - - 1.03 - - - 5.2 - 5.12 4.31 4.98 - 5.04 5.23 4.58 - 4.23 2.68 2.14 - 2.16 2.58 2.22 - 1.76 1.64 1.35 - 1.13 1.13 0.81 - 1.11 0.68 0.66 - 1.12 1.02 0.69 - 0.71 0.95 0.88 - 0.72 0.95 0.81 - 0.87 0.54 0.62 - 0.64 0.78 0.82

ROE %

 -2.56 -1.34 0.27 -2.65 0.15 0.51 12.50 28.27 55.63 51.69 75.71 93.93 96.96 73.57 94.96 95.06 88.34 68.99 86.80 87.31 77.14 65.41 66.57 59.83 66.28 74.32 69.71 67.17 59.72 51.13 43.64 37.17 31.20 25.66 23.09 23.24 19.80 18.58 18.65 18.55 22.06 22.64 24.32 25.21 25.57 20.56 26.32 27.47 26.39 18.98 26.92 24.25 21.46 15.43 22.34 22.50 28.06 23.67 6.91 8.10 8.66

ROA %

 -1.95 -1.04 0.19 -1.75 0.08 0.36 7.58 16.70 31.90 29.16 40.23 42.92 44.72 32.30 45.19 34.11 46.69 36.78 46.92 48.09 43.14 37.26 37.33 33.02 36.06 40.03 39.05 39.02 36.37 32.93 28.70 25.14 22.00 19.00 17.38 17.80 15.41 14.71 14.64 14.33 16.86 17.13 17.99 18.24 18.06 14.27 18.55 19.69 19.23 14.08 19.62 17.50 15.23 10.76 15.55 15.65 19.50 16.44 4.80 5.63 6.02

ROCE %

 -6.26 -4.66 -1.98 -3.91 0.34 0.94 14.16 34.00 69.15 65.38 97.38 121.98 126.62 95.31 123.42 122.99 115.36 89.86 118.20 107.95 91.36 61.17 80.50 78.26 83.96 69.00 85.01 81.36 68.72 45.15 54.57 48.97 41.22 27.76 37.09 32.90 29.01 21.09 30.09 30.54 32.66 26.13 34.32 37.57 39.74 32.38 39.85 42.48 38.94 27.00 36.83 34.43 30.37 21.66 30.80 33.30 42.00 35.24 9.14 12.34 13.76

Current Ratio

 4.1 4.6 5.0 5.0 4.1 3.8 3.5 3.3 3.3 2.9 2.5 2.4 2.1 2.0 1.9 - 2.0 2.0 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.8 2.8 2.8 2.8 3.9 3.9 3.9 3.9 4.8 4.8 4.8 4.8 4.2 4.1 4.1 4.1 3.3 3.3 3.3 3.3 3.9 3.9 3.9 3.9 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3

DSO

 - - - - - - - - - - 0.1 - - - - - 0.0 - 0.0 0.0 0.1 0.2 0.2 0.2 0.5 0.8 0.7 0.7 0.7 0.6 0.7 0.8 0.7 0.7 0.7 0.7 1.3 2.0 1.9 1.8 1.9 2.4 2.3 2.1 2.0 - 2.2 2.0 1.5 - 1.3 1.2 1.6 - 2.1 2.1 1.9 - 1.8 1.7 -

DIO

 84.5 83.8 89.4 109.8 118.5 - 105.4 86.8 97.0 - 99.2 88.5 96.0 - 61.6 65.5 146.0 - 96.7 71.8 57.3 - 72.2 80.3 107.8 - 94.4 95.9 98.2 - 110.8 124.4 111.7 - 92.7 97.3 96.9 - 101.8 93.2 75.4 - 72.5 64.1 67.7 - 78.5 75.0 71.2 - 76.2 68.3 75.0 - 83.9 81.0 83.9 - 92.8 94.8 -

DPO

 - - - - - - - - - - - - - - - - 28.1 - - - 17.9 - - - 23.9 - - - 21.3 - - - 26.5 - - - 24.6 - - - - - - - - - - - 57.3 - - - 54.5 - - - 38.8 - - - -

Operating Cycle

 - - 89.4 109.8 118.5 - 105.4 86.8 97.0 - 99.2 88.5 96.0 - 61.6 65.5 146.0 - 96.7 71.8 57.4 0.2 72.5 80.5 108.3 0.8 95.1 96.6 98.9 0.6 111.4 125.2 112.4 0.7 93.4 98.0 98.1 2.0 103.6 95.0 77.3 2.4 74.8 66.1 69.7 - 80.7 77.0 72.7 - 77.5 69.4 76.6 - 86.0 83.1 85.8 - 94.6 96.6 -

Cash Conversion Cycle

 - - 89.4 109.8 118.5 - 105.4 86.8 97.0 - 99.2 88.5 96.0 - 61.6 65.5 118.0 - 96.7 71.8 39.5 0.2 72.5 80.5 84.5 0.8 95.1 96.6 77.6 0.6 111.4 125.2 85.9 0.7 93.4 98.0 73.5 2.0 103.6 95.0 77.3 2.4 74.8 66.1 69.7 - 80.7 77.0 15.4 - 77.5 69.4 22.1 - 86.0 83.1 47.0 - 94.6 96.6 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Medifast, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Personal services industry

Issuer Price % 24h Market Cap Country
Carriage Services Carriage Services
CSV
 		$ 34.09 0.26 % $ 526 M usaUSA
frontdoor frontdoor
FTDR
 		$ 82.89 0.09 % $ 6.06 B usaUSA
Franchise Group Franchise Group
FRG
 		- - $ 1.17 B usaUSA
Terminix Global Holdings Terminix Global Holdings
TMX
 		- - $ 4.6 B usaUSA
Bright Horizons Family Solutions Bright Horizons Family Solutions
BFAM
 		$ 74.81 0.58 % $ 4.26 B usaUSA
H&R Block H&R Block
HRB
 		$ 52.48 0.59 % $ 6.7 B usaUSA
StoneMor StoneMor
STON
 		- 0.57 % $ 419 M usaUSA
MEDIROM Healthcare Technologies MEDIROM Healthcare Technologies
MRM
 		$ 0.95 1.06 % $ 4.85 M japanJapan
Service Corporation International Service Corporation International
SCI
 		$ 83.36 0.16 % $ 11.8 B usaUSA
Regis Corporation Regis Corporation
RGS
 		$ 27.13 1.59 % $ 64.1 M usaUSA
Rollins Rollins
ROL
 		$ 36.38 1.22 % $ 17.6 B usaUSA
WW International WW International
WW
 		$ 16.2 0.44 % $ 162 M usaUSA